{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:30Z","timestamp":1791908190809,"version":"4.3.4"},"reference-count":90,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Support Foundation of the State of S\u00e3o Paulo","award":["#2016\/23765-0"],"award-info":[{"award-number":["#2016\/23765-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Invasive and somatostatin receptor ligand (SRL)-resistant pituitary tumors represent a challenge in the clinical practice of endocrinologists. Efforts have been made to elucidate reliable makers for both. Survivin and eukaryotic translation initiation factor-binding protein 1 (4EBP1) are upregulated in several cancers and involved in apoptosis and cell proliferation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We explored the role of these markers in somatotropinomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Immunostains for survivin and 4EBP1, and also for somatostatin receptor type 2 (SSTR2), Ki-67, and cytokeratin 18, were analyzed in tissue microarrays containing 52 somatotropinoma samples. Tumor invasiveness was evaluated in all samples while drug resistance was evaluated in 34 patients who received SRL treatment. All these parameters were correlated with first-generation SRL (fg-SRL) responsiveness and tumor invasiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Low survivin expression (P = 0.04), hyperintense signal on T2 weighted image (T2WI) (P = 0.01), younger age (P = 0.01), sparsely granular adenomas (SGA) (P = 0.04), high postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels (P = 0.049 and P &amp;lt; 0.001, respectively), and large postoperative tumor size (P = 0.02) were associated with resistance to fg-SRL. Low survivin and SSTR2 expression and high 4EBP1 expression were associated with SGA (P = 0.04, P = 0.01, and P = 0.001, respectively). Younger age (P = 0.03), large tumor pre- and postoperative (P = 0.04 and P = 0.006, respectively), low SSTR2 expression (P = 0.03), and high baseline GH and IGF-1 (P = 0.01 and P = 0.02, respectively) were associated with tumor invasiveness. However, survivin, 4EBP1, Ki-67, and granulation patterns were not associated with tumor invasion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests that low survivin expression is predictive of resistance to fg-SRL in somatotropinomas, but not of tumor invasiveness.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac610","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:57:59Z","timestamp":1666576679000},"page":"876-887","source":"Crossref","is-referenced-by-count":9,"title":["Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-6974","authenticated-orcid":false,"given":"Clarissa G Borba","family":"Herkenhoff","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-2439","authenticated-orcid":false,"given":"Ericka B","family":"Trarbach","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular and Molecular Endocrinology\/LIM25 Division of Endocrinology and Metabology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5461-0301","authenticated-orcid":false,"given":"Rafael Loch","family":"Batista","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"},{"name":"Service of Endocrine Oncology, Cancer Institute of the State of S\u00e3o Paulo (ICESP), Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-4686","authenticated-orcid":false,"given":"Iber\u00ea Cauduro","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-6834","authenticated-orcid":false,"given":"Fernando Pereira","family":"Frassetto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-3386","authenticated-orcid":false,"given":"Felipe Barjud Pereira","family":"do Nascimento","sequence":"additional","affiliation":[{"name":"Department of Radiology and Diagnostic Imaging, Hospital Israelita Albert Einstein , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-4286","authenticated-orcid":false,"given":"Isabella Pacetti Pajaro","family":"Grande","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular and Molecular Endocrinology\/LIM25 Division of Endocrinology and Metabology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-2202","authenticated-orcid":false,"given":"Paula P B","family":"Silva","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-1301","authenticated-orcid":false,"given":"Felipe H G","family":"Duarte","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-5201","authenticated-orcid":false,"given":"Marcello D","family":"Bronstein","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"},{"name":"Laboratory of Cellular and Molecular Endocrinology\/LIM25 Division of Endocrinology and Metabology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1892","authenticated-orcid":false,"given":"Raquel S","family":"Jallad","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"},{"name":"Laboratory of Cellular and Molecular Endocrinology\/LIM25 Division of Endocrinology and Metabology, Clinics Hospital, University of S\u00e3o Paulo Medical School , S\u00e3o Paulo, CEP 05403-010 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"issue":"10","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.23736\/S0391-1977.19.02970-5","article-title":"Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors","volume":"44","author":"Fuentes-Fayos","year":"2019","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1038\/s41598-018-24260-y","article-title":"Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas","volume":"8","author":"Alhambra-Exp\u00f3sito","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.1992.tb02304.x","article-title":"The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex","volume":"37","author":"van der Lely","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.01824","article-title":"Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs","volume":"152","author":"Petrossians","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/jc.2008-1420","article-title":"Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-016-0768-4","article-title":"Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance","volume":"20","author":"Paragliola","year":"2017","journal-title":"Pituitary"},{"issue":"Suppl 3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas","volume":"8","author":"Tortora","year":"2019","journal-title":"Gland Surg"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jcmm.13427","article-title":"Molecular evidence and clinical importance of \u03b2-arrestins expression in patients with acromegaly","volume":"22","author":"Coelho","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/biomedicines10020460","article-title":"Implications of heterogeneity of epithelial-mesenchymal states in acromegaly therapeutic pharmacologic response","volume":"10","author":"Gil","year":"2022","journal-title":"Biomedicines"},{"issue":"Suppl 3","key":"2023031010321228200_","first-page":"e59","article-title":"Correlation between the expression of interleukin-6, STAT3, E-cadherin and N-cadherin protein and invasiveness in nonfunctional pituitary adenomas","volume":"82","author":"Shen","year":"2021","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41598-018-37692-3","article-title":"Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles","volume":"9","author":"Coelho","year":"2019","journal-title":"Sci Rep"},{"key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2020.10.004","article-title":"Cytokeratin profiles in pituitary neuroendocrine tumors","volume":"107","author":"Asa","year":"2021","journal-title":"Hum Pathol"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort ofpatients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1677\/ERC-09-0101","article-title":"Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors","volume":"16","author":"Dworakowska","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"e2291","DOI":"10.1210\/clinem\/dgac128","article-title":"The p300 inhibitor A-485 exerts antitumor activity in growth hormone pituitary adenoma","volume":"107","author":"Ji","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12020-017-1432-0","article-title":"PI3K\/Akt\/mTOR Pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line","volume":"60","author":"Di Pasquale","year":"2018","journal-title":"Endocrine"},{"key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.2147\/OTT.S270076","article-title":"MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro [retraction]","volume":"13","author":"Zhou","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"jcs223826","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J Cell Sci"},{"issue":"62","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"105637","DOI":"10.18632\/oncotarget.22354","article-title":"Survivin overexpression is potentially associated with pituitary adenoma invasiveness","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"11","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023031010321228200_","author":"Borba"},{"issue":"9","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"issue":"6","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3171\/2019.3.JNS19367","article-title":"Challenging Knosp high-grade pituitary adenomas","volume":"132","author":"Micko","year":"2019","journal-title":"J Neurosurg"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"issue":"11","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1478-3231.2010.02370.x","article-title":"Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?","volume":"31","author":"Stefano","year":"2011","journal-title":"Liver Int"},{"issue":"3","key":"2023031010321228200_","first-page":"138","article-title":"[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"issue":"3","key":"2023031010321228200_","first-page":"187","article-title":"Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors","volume":"5","author":"Kaemmerer","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-SST2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00432-022-04013-1","article-title":"Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis","volume":"148","author":"Krieg","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0971-5916.159250","article-title":"Survivin: a molecular biomarker in cancer","volume":"141","author":"Jaiswal","year":"2015","journal-title":"Indian J Med Res"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2012.03.005","article-title":"Targeting survivin in cancer","volume":"332","author":"Altieri","year":"2013","journal-title":"Cancer Lett"},{"issue":"43","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.3748\/wjg.v27.i43.7546","article-title":"Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma","volume":"27","author":"Yu","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"23","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.18632\/oncotarget.27631","article-title":"Exploring the role of survivin in neuroendocrine neoplasms","volume":"11","author":"Hanif","year":"2020","journal-title":"Oncotarget"},{"issue":"44","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.18632\/oncotarget.27054","article-title":"Effect of ASA on pituitary adenomas: is it a matter of survivin?","volume":"10","author":"Rotondo","year":"2019","journal-title":"Oncotarget"},{"issue":"49","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"29180","DOI":"10.18632\/oncotarget.25650","article-title":"Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas","volume":"9","author":"N\u00e9meth","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5603\/FHC.a2017.0002","article-title":"Decreased expression of survivin 2B in human pituitary adenomas. A preliminary study","volume":"55","author":"Waligorska-Stachura","year":"2017","journal-title":"Folia Histochem Cytobiol"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12022-012-9197-8","article-title":"Expression and clinical significance of Wnt players and survivin in pituitary tumours","volume":"23","author":"Formosa","year":"2012","journal-title":"Endocr Pathol"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"F734","DOI":"10.1152\/ajprenal.00546.2012","article-title":"Renal uptake of the antiapoptotic protein survivin is mediated by megalin at the apical membrane of the proximal tubule","volume":"305","author":"Jobst-Schwan","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2353\/ajpath.2007.070132","article-title":"The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney","volume":"171","author":"Lechler","year":"2007","journal-title":"Am J Pathol"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00223-011-9508-y","article-title":"The oncofetal gene survivin promotes cell proliferation and survival in primary human osteoblastic cells","volume":"89","author":"Lechler","year":"2011","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2023031010321228200_","first-page":"209","article-title":"Survivin expression in pituitary adenomas","volume":"26","author":"Wasko","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"issue":"14","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1007\/s00018-021-03864-0","article-title":"Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination","volume":"78","author":"Reich","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1083\/jcb.201609061","article-title":"Dual recognition of chromatin and microtubules by INCENP is important for mitotic progression","volume":"216","author":"Wheelock","year":"2017","journal-title":"J Cell Biol"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4161\/cc.6.5.3902","article-title":"Survivin's dual role: an export's View","volume":"6","author":"Knauer","year":"2007","journal-title":"Cell Cycle"},{"issue":"12","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/sj.cdd.4401091","article-title":"Differential subcellular localization of functionally divergent survivin splice variants","volume":"9","author":"Mahotka","year":"2002","journal-title":"Cell Death Differ"},{"issue":"8","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cancers12030577","article-title":"Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines","volume":"12","author":"Michaelis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/cancers12051080","article-title":"YM155-adapted Cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting","volume":"12","author":"Michaelis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"e2410","DOI":"10.1038\/cddis.2016.257","article-title":"Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance","volume":"7","author":"Voges","year":"2016","journal-title":"Cell Death Dis"},{"key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000094315","article-title":"Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome","volume":"35","author":"Bronstein","year":"2006","journal-title":"Front Horm Res"},{"key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40618-021-01609-1","article-title":"Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines","volume":"45","author":"Dicitore","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1-2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000500812","article-title":"A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells","volume":"110","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11102-014-0590-9","article-title":"Evaluation of survivin splice variants in pituitary tumors","volume":"18","author":"Walig\u00f3rska-Stachura","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ijc.10450","article-title":"Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas","volume":"100","author":"Mahotka","year":"2002","journal-title":"Int J Cancer"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00432-008-0433-z","article-title":"Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma","volume":"135","author":"De Maria","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11102-011-0369-1","article-title":"Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values?","volume":"15","author":"Brzana","year":"2012","journal-title":"Pituitary"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","article-title":"Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas","volume":"59","author":"Kato","year":"2012","journal-title":"Endocr J"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/EJE-13-0134","article-title":"Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas","volume":"169","author":"Mayr","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1530\/ERC-14-0188","article-title":"The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas","volume":"21","author":"Monsalves","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/en.2012-1908","article-title":"Inhibition of PI3K\/AKT\/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice","volume":"154","author":"Dai","year":"2013","journal-title":"Endocrinology"},{"issue":"6","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11154-020-09557-6","article-title":"Neuroimaging of aggressive pituitary tumors","volume":"21","author":"Bonneville","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2023031010321228200_","first-page":"835","article-title":"Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting response to somatostatin analogs in acromegaly patients","volume":"29","author":"Durmaz","year":"2019","journal-title":"Turk Neurosurg"},{"issue":"12","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00234-019-02266-1","article-title":"Prediction of high proliferative index in pituitary macroadenomas using MRI-based radiomics and machine learning","volume":"61","author":"Ugga","year":"2019","journal-title":"Neuroradiology"},{"issue":"6","key":"2023031010321228200_","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1210\/jc.2005-2110","article-title":"Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac610\/47012334\/dgac610.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/4\/876\/49499543\/dgac610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/4\/876\/49499543\/dgac610.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:13:51Z","timestamp":1701260031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/4\/876\/6770120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":90,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,24]]},"published-print":{"date-parts":[[2023,3,10]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac610","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,10,24]]}}}